search
Back to results

A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults (15KMHI)

Primary Purpose

Resting Metabolic Rate, Overweight Subjects

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
7-Keto 50mg
7-Keto 25mg
Placebo
Sponsored by
KGK Science Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Resting Metabolic Rate focused on measuring Resting Metabolic Rate, 7-Keto-DHEA, Efficacy, Overweight Adults, Obese Adults

Eligibility Criteria

20 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female 20 to 55 years of age
  2. If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).

    OR

    Female subject of childbearing potential must agree to use a medically approved method of non-hormonal birth control and have a negative urine pregnancy test result. Birth Control methods must be initiated at least 14 days prior to randomization and must be continued until 28 days after the end of study visit. Acceptable methods of birth control include:

    • Double barrier method
    • Intrauterine devices (non-hormonal)
    • Cervical caps or sponges
    • Use of male/female condom
    • Vasectomy of partner
    • Non-heterosexual lifestyle
  3. If female and currently experiencing menstrual cycles, subjects should have regular menstrual cycles (28 ± 2 days) and must be in their follicular phase during the duration of the study period (i.e. baseline to visit 3)
  4. BMI 25-34.9 ±1 kg/m2
  5. Stable weight defined as less than 5kg (approx. 11lbs) gained or lost in the past 3 months
  6. Sedentary subjects; defined as subjects with a desk/inactive job, not engaging in any regular sports or exercise programs either at an exercise facility or at home. Occasional activity, low intensity yoga and walking at a regular pace are acceptable.
  7. Agreement to maintain current level of physical activity through the study and avoid exercising 24 hours prior to study visits
  8. Agreement to adopt a diet with a 500 kcal reduction for the duration of the study period.
  9. Agreement to completely avoid caffeine consumption, such as coffee, tea and soft drinks 24 hours before study visits and to limit consumption of coffee, tea and soft drinks to 2 cups per day for all other days during the study.
  10. Agreement to completely avoid consumption of energy drinks for 24 hours before the screening and baseline visits and for the duration of the study.
  11. Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  2. Immunodeficiency (i.e. HIV positive, rheumatoid arthritis, history of organ transplant)
  3. Use of tobacco products and nicotine products.
  4. Use of prescription, over-the-counter, or natural health products known to affect weight and/or metabolic rate within 4 weeks of randomization and during the trial
  5. Unstable medical conditions
  6. Uncontrolled blood pressure (i.e. systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg)
  7. Type I or II diabetes, metabolic disease or any condition that in the opinion of the Qualified Investigator does not safely allow for a reduction in calorie intake
  8. Any evidence of an eating disorder, such as anorexia or bulimia, or the presence of any illness that might represent a potential cause of weight loss
  9. Abnormal ECG at screening
  10. Clinically significant abnormal laboratory results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN; serum creatinine > 1.5 x ULN)
  11. Currently taking anti-psychotic medication
  12. Participation in a clinical research trial within 30 days prior to randomization
  13. Allergy or sensitivity to study supplement ingredients
  14. Alcohol abuse (>2 standard alcoholic drinks per day)
  15. Current drug abuse or drug abuse within the past 6 months
  16. Use of marijuana for medical purposes
  17. Individuals who are cognitively impaired and/or who are unable to give informed consent
  18. Any other condition, which in the Investigator's opinion, may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Sites / Locations

  • KGK USA
  • KGK USA

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo

7-Keto 50mg

7-Keto 25mg

Arm Description

Outcomes

Primary Outcome Measures

Change in resting metabolic rate

Secondary Outcome Measures

Change in total body water
Change in total body fat

Full Information

First Posted
March 1, 2021
Last Updated
April 22, 2021
Sponsor
KGK Science Inc.
Collaborators
InterHealth Nutraceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04782024
Brief Title
A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults
Acronym
15KMHI
Official Title
A Randomized, Double-Blind, Placebo Controlled Parallel Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
September 30, 2015 (Actual)
Primary Completion Date
November 4, 2016 (Actual)
Study Completion Date
November 4, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KGK Science Inc.
Collaborators
InterHealth Nutraceuticals, Inc.

4. Oversight

5. Study Description

Brief Summary
This study will investigate the effect of two different doses of 7-Keto compared to placebo on resting metabolic rate. One third of subjects will be given the lower 7-Keto dose, one third will be given the higher 7-Keto dose and one third will be given the placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resting Metabolic Rate, Overweight Subjects
Keywords
Resting Metabolic Rate, 7-Keto-DHEA, Efficacy, Overweight Adults, Obese Adults

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
138 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
7-Keto 50mg
Arm Type
Experimental
Arm Title
7-Keto 25mg
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
7-Keto 50mg
Intervention Type
Dietary Supplement
Intervention Name(s)
7-Keto 25mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in resting metabolic rate
Time Frame
1 week: from baseline to end of study
Secondary Outcome Measure Information:
Title
Change in total body water
Time Frame
1 week: from baseline to end of study
Title
Change in total body fat
Time Frame
1 week: from baseline to end of study
Other Pre-specified Outcome Measures:
Title
Number of incidents of abnormal lab results
Description
Lab results from blood biochemistry and hematology (Na, K, Cl, creatinine, BUN, AST, ALT, GGT and bilirubin)
Time Frame
1 week: from baseline to end of study
Title
Number of incidents of adverse events
Time Frame
1 week: from baseline to end of study
Title
Change in BMI
Time Frame
1 week: from baseline to end of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female 20 to 55 years of age If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation). OR Female subject of childbearing potential must agree to use a medically approved method of non-hormonal birth control and have a negative urine pregnancy test result. Birth Control methods must be initiated at least 14 days prior to randomization and must be continued until 28 days after the end of study visit. Acceptable methods of birth control include: Double barrier method Intrauterine devices (non-hormonal) Cervical caps or sponges Use of male/female condom Vasectomy of partner Non-heterosexual lifestyle If female and currently experiencing menstrual cycles, subjects should have regular menstrual cycles (28 ± 2 days) and must be in their follicular phase during the duration of the study period (i.e. baseline to visit 3) BMI 25-34.9 ±1 kg/m2 Stable weight defined as less than 5kg (approx. 11lbs) gained or lost in the past 3 months Sedentary subjects; defined as subjects with a desk/inactive job, not engaging in any regular sports or exercise programs either at an exercise facility or at home. Occasional activity, low intensity yoga and walking at a regular pace are acceptable. Agreement to maintain current level of physical activity through the study and avoid exercising 24 hours prior to study visits Agreement to adopt a diet with a 500 kcal reduction for the duration of the study period. Agreement to completely avoid caffeine consumption, such as coffee, tea and soft drinks 24 hours before study visits and to limit consumption of coffee, tea and soft drinks to 2 cups per day for all other days during the study. Agreement to completely avoid consumption of energy drinks for 24 hours before the screening and baseline visits and for the duration of the study. Has given voluntary, written, informed consent to participate in the study Exclusion Criteria: Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial Immunodeficiency (i.e. HIV positive, rheumatoid arthritis, history of organ transplant) Use of tobacco products and nicotine products. Use of prescription, over-the-counter, or natural health products known to affect weight and/or metabolic rate within 4 weeks of randomization and during the trial Unstable medical conditions Uncontrolled blood pressure (i.e. systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) Type I or II diabetes, metabolic disease or any condition that in the opinion of the Qualified Investigator does not safely allow for a reduction in calorie intake Any evidence of an eating disorder, such as anorexia or bulimia, or the presence of any illness that might represent a potential cause of weight loss Abnormal ECG at screening Clinically significant abnormal laboratory results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN; serum creatinine > 1.5 x ULN) Currently taking anti-psychotic medication Participation in a clinical research trial within 30 days prior to randomization Allergy or sensitivity to study supplement ingredients Alcohol abuse (>2 standard alcoholic drinks per day) Current drug abuse or drug abuse within the past 6 months Use of marijuana for medical purposes Individuals who are cognitively impaired and/or who are unable to give informed consent Any other condition, which in the Investigator's opinion, may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Facility Information:
Facility Name
KGK USA
City
Foothill Ranch
State/Province
California
ZIP/Postal Code
92610
Country
United States
Facility Name
KGK USA
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults

We'll reach out to this number within 24 hrs